Our discovery platform simultaneously evaluates drug efficacy, specificity and toxicity in single living cells over time.
Restoring normal protein production from healthy genes can slow, or even reverse, the progression of many genetic diseases.
Genetic diseases affect hundreds of millions of people worldwide. Many result from the mutation or deletion of one gene copy, where the remaining healthy allele cannot compensate and produce enough protein.
Geneboost programs focus on the discovery and development of drugs that increase protein production from healthy alleles of haploinsufficient genes. Our technology enables real-time, non-invasive detection of protein synthesis specifically from healthy alleles for any genetic disease. We identify therapies that can boost production from the healthy allele.
Geneboost is seeking strategic partnerships and collaborators interested in early-stage drug discovery projects and services.
The tools currently used to assay gene expression can be error-prone, time-consuming and costly, and they represent a rate-limiting step in the effort to study new disease targets. New target-specific antibodies must usually be created for every novel target, and commonly used fluorescent fusion proteins can reliably track only a fraction of mammalian proteins.
By simultaneously monitoring multiple endogenous genes to assess drug efficacy, specificity, and adverse effects in single living cells over time, our platform reduces the time and cost of the earliest stages of drug discovery by more than tenfold.
Our proprietary technology streamlines the workflow from in silico target selection to drug screening in less than one month — allowing key target-suitability decisions to be made more rapidly, and bringing better therapeutic candidates to the clinic.
Patents granted. Our platform is backed by a portfolio of four patents spanning drug discovery, protein production, and vaccine production technologies.
Geneboost grew out of research at McGill University, translating discoveries in single-cell biology into a faster, more reliable way to find drugs. We bring together expertise across neuroscience, molecular biology and genome engineering.
We work closely with academic and industry partners on early-stage discovery programs, and we're always open to new collaborations.
Interested in a partnership, a screening project, or licensing our technology? Send a note and we'll get back to you.
Montréal, Québec, Canada
Geneboost